Dataset opportunity
Ceryxmedical — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Ceryxmedical, usable for Diagnostic AI and Computer Vision.
Score
69.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global artificial intelligence in diagnostics market size was valued at USD 2.0 billion in 2025, projected to reach USD 9.7 billion by 2033, at a CAGR of 21.7%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 🤝Data partnership
Collaboration with University of Auckland for physiological studies
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Ceryxmedical holds a unique Medical Imaging Dataset derived from sensitive physiological signals, including `iot_data` and `medical_records` from its clinical and pre-clinical trials. This high-value data, focused on bioelectronic signals for cardiac rhythm control, is structured for developing and validating Diagnostic AI models, with its usability further enhanced by associated regulatory documentation.
The global AI in diagnostics market was valued at USD 2.0 billion in 2025 and is projected to grow at a CAGR of 21.7% through 2033. [1] Despite strict access conditions due to GDPR, ethical compliance for clinical trial data, and intertwined proprietary algorithms, the rarity and specificity of this dataset make it a critical asset for buyers aiming to innovate in a market with such significant growth. ⚠ Diligence (valuable data, access to negotiate): Data involves sensitive physiological signals from clinical and pre-clinical trials.; Highly regulated medical device sector requires strict ethical and GDPR compliance for data transfer.; Proprietary bioelectronic signal processing algorithms may be intertwined with raw data. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Ceryxmedical owns a proprietary, multi-modal dataset centered on heart failure. It uniquely combines high-resolution cardiac recordings, patented bioelectronic time-series data, and information from clinical trials. This is a rare and powerful asset for diagnostic AI companies aiming to develop and validate sophisticated predictive models for the cardiac sector, a key driver in the AI diagnostics market projected to reach $9.7 billion by 2033.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is exceptionally high, driven by the rapid expansion of the AI in diagnostics market, which is growing at a 21.7% CAGR. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Ceryx Medical is a good target as it's an SME developing a physical medical device (pacemaker) and the valuable clinical trial data generated is a by-product of this core operational business, not its primary product for sale.
- Deep Qualification70
⚠ needs review — Ceryx Medical is a medical device developer whose core business is selling a bioelectronic pacemaker, not data. It holds a valuable by-product dataset of physiological signals from its pre-clinical and human trials, but the 'Medical Imaging' label is incorrect. Data ownership is likely mixed and licensing rights are unclear due to the complexities of clinical trial agreements and patient consent. [dataset_type implausible vs real activity: The company's product, Cysoni, monitors and processes physiological signals from the cardiorespiratory system, which is time-series data, not a 'Medical Imaging Dataset'. [7, 8]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The dataset contains high-resolution recordings of cardiac function, including heart rate variability from clinical heart failure models, providing the granular detail needed to train AI for early and accurate disease detection.
IoT / sensor data
This evidence points to exclusive time-series data from patented bioelectronic devices that monitor homeostatic system interactions, offering a unique, real-time physiological signal for developing predictive and personalized diagnostic algorithms.
Regulatory records
The dataset is enriched with data from clinical trials focused on improving patient outcomes in heart failure, a critical asset for any AI developer needing to validate model performance and efficacy against real-world therapeutic interventions.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Ceryxmedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global artificial intelligence in diagnostics market size was valued at USD 2.0 billion in 2025, projected to reach USD 9.7 billion by 2033, at a CAGR of 21.7% (source: Grand View Research). [1]. Investment score 69.5/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Acusurgical — Medical Imaging Dataset Opportunity
View opportunity →healthcareArtoptical — Medical Imaging Dataset Opportunity
View opportunity →healthcareZetasurgical — Image Dataset Opportunity
View opportunity →